Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
about
Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesisHuman leukocyte Antigen-DM polymorphisms in autoimmune diseasesHLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanismAltered major histocompatibility complex class II peptide loading in H2-O-deficient miceThe contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.SNP association mapping across the extended major histocompatibility complex and risk of B-cell precursor acute lymphoblastic leukemia in children.Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM.Dissociation of peripheral T cell responses from thymocyte negative selection by weak agonists supports a spare receptor model of T cell activation.HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesHLA-DO as the optimizer of epitope selection for MHC class II antigen presentation.Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules.Right place, right time, right peptide: DO keeps DM focused.pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity.Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development.MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes.Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO.Functional analysis of tryptophans alpha 62 and beta 120 on HLA-DM.Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.The HLA-DOB gene displays limited polymorphism with only one amino acid substitution.CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides.
P2860
Q24338938-C9D580E0-8EEA-4FA7-9598-D3E3EC3E3B94Q26741035-0ED3E4D5-FFC7-425E-9480-3F4B583E31CCQ27675409-5897A6DC-5CDF-48AB-B580-71DF30DF8911Q28510157-0BAEF1F1-8A6A-46C4-90A8-6E66F7FC2856Q30444065-C71298C7-94E4-4DD0-B874-32041025CD98Q31133047-D1BDE51B-C460-405B-9076-8E6F83776DB8Q33707475-DB5CB5BA-14AB-4248-8C59-70399EEBAD05Q33772095-B3D70C83-4F33-4D3E-BB3F-66D34E5738D6Q34048781-03BFC036-9A3B-447C-A0FA-4EE1439F93D7Q34412690-52220F8C-725D-4A66-9295-85AF6EE30817Q34462167-BB387935-1D84-40A0-9A95-36CAAC814D0CQ34948997-D1055E14-B4E5-4194-B5CD-80F76C2F2164Q35540109-46D82A9D-59E7-43B4-96A1-93C9DC58B14EQ35821240-0014F5ED-BD1A-40D0-8089-A1BA00DD6881Q36266508-09693A3B-E642-499C-9948-1D6A9D5CAF2AQ36323798-8F1D319C-889B-4E11-A878-69184639FB37Q36370114-87BCF07C-93FE-4086-9A3B-0CAD5D64E52BQ37189146-B8BBD59C-B842-4793-A66E-25BCAB4063DDQ37773238-9F568419-0A11-4C3D-9BFC-EE99986E06DEQ38167996-B81C997A-6681-4A43-A04B-191FDAF6461FQ39712353-18B9F157-4D6F-4973-91EE-90C78EC7ABB3Q40737770-0E1BD7E6-6FCA-4486-89A9-3252120E2E83Q43802418-EA960B3F-BD5E-4FC5-B200-BFDC962AAA58Q48171420-09843839-5BDF-4767-9762-67F5F26ADE05Q48272625-1536579B-1337-412B-A215-B91AA2051904Q48371221-3EBA0164-0F3F-4B74-ABC4-9E3FCD0D6C6B
P2860
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Modulation of the major histoc ...... ty leukocyte antigen (HLA)-DO.
@en
Modulation of the major histoc ...... ompatibility leukocyte antigen
@nl
type
label
Modulation of the major histoc ...... ty leukocyte antigen (HLA)-DO.
@en
Modulation of the major histoc ...... ompatibility leukocyte antigen
@nl
prefLabel
Modulation of the major histoc ...... ty leukocyte antigen (HLA)-DO.
@en
Modulation of the major histoc ...... ompatibility leukocyte antigen
@nl
P2093
P2860
P50
P356
P1476
Modulation of the major histoc ...... ity leukocyte antigen (HLA)-DO
@en
P2093
B Lillemeier
J Trowsdale
K van Meijgaarden
L Pastoors
T Ottenhoff
P2860
P304
P356
10.1084/JEM.191.7.1127
P407
P577
2000-04-01T00:00:00Z